GO:0140211 folic acid:proton symporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140211 folic acid:proton symporter activity describes the proton-coupled transfer of folic acid and reduced folates across membranes, primarily mediated by PCFT/SLC46A1 [1,2].
• PCFT/SLC46A1 is the main molecular entity responsible for this activity and shows similar affinity for folic acid and reduced folates such as 5-methyl THF and 5-formyl THF [2,5].
• This transport activity is pH-dependent, operating optimally at acidic pH in the intestine, placenta, kidney, and central nervous system [1,2,6,8].
• Dysregulation of folic acid:proton symporter activity is linked to gestational diabetes, hyperleptinemia, and TNF-α exposure in placental models.
• Methotrexate, an antifolate drug, is transported via folate transporters including PCFT, making this activity relevant to chemotherapy pharmacology.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of SLC46A1 and related folate transport genes [1,8].
Description
Folic acid:proton symporter activity (GO:0140211) is a molecular function that enables the transfer of folic acid and reduced folates across biological membranes in a proton-coupled manner [1,2]. This activity is essential for cellular uptake of folates, which are required for one-carbon metabolism, nucleotide synthesis, and methylation reactions. The main molecular entity responsible for this activity is the Proton-Coupled Folate Transporter (PCFT), encoded by SLC46A1, which exhibits similar affinity for folic acid and reduced folates such as 5-methyl THF and 5-formyl THF [2,5]. Researchers study this term because folate transport is critical for normal development, and its dysfunction is implicated in intestinal, placental, renal, and neurological disorders [1,6,7,8]. The activity is pH-dependent, functioning optimally in acidic environments such as the intestinal lumen and tumor microenvironment [1,2]. Understanding the molecular mechanism of folic acid:proton symporter activity provides a foundation for targeting folate metabolism in cancer and inflammatory diseases [5,7].
folic acid:proton symporter activity At A Glance
| GO ID | GO:0140211 |
|---|---|
| GO term | folic acid:proton symporter activity |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Proton-coupled transport of folic acid and reduced folates across membranes |
| Main transporter | PCFT/SLC46A1 |
| Substrates | Folic acid, 5-methyl THF, 5-formyl THF |
| Reaction | folic acid(out) + H+(out) = folic acid(in) + H+(in) |
| Tissue distribution | Intestine, placenta, kidney, choroid plexus, corneal epithelium |
What Is GO:0140211?
According to the Gene Ontology, GO:0140211 folic acid:proton symporter activity enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: folic acid(out) + H+(out) = folic acid(in) + H+(in). The main folic acid symporter is the Proton-Coupled Folate Transporter (PCFT/SLC46A1), which has similar affinity for transport of reduced folates (5-methyl THF, 5-formyl THF) and folic acid [1,2].
Why Is folic acid:proton symporter activity Important in Cell Biology?
Folic acid:proton symporter activity is essential for folate homeostasis in rapidly dividing cells and across epithelial barriers. It supports intestinal absorption, placental transfer, renal reabsorption, and central nervous system folate delivery [1,2,6,8]. Because folates are required for DNA synthesis and methylation, defects in this activity can lead to megaloblastic anemia, neural tube defects, and chemotherapy resistance [5,7]. The pH-dependent nature of this transport makes it a potential target for drug delivery and antimalarial strategies.
• Critical for intestinal folate absorption at acidic pH.
• Mediates placental folate transfer, affected by gestational diabetes and inflammation.
• Enables renal folate reabsorption, with adaptive upregulation in deficiency.
• Localized in the central nervous system, contributing to brain folate homeostasis.
• Transports methotrexate, impacting chemotherapy efficacy.
• Expressed in corneal epithelium, relevant for ocular drug delivery.
• Targeted in antimalarial drug discovery as a potential drug target.
• Dysregulation linked to hyperleptinemia and TNF-α in trophoblast models.
• Provides a mechanism for pH-dependent folate uptake in tumors.
• Enables functional characterization of folate transport proteins in vitro [2,3].
Molecular Mechanism of folic acid:proton symporter activity
Proton-coupled folate transport
In simple terms: Folic acid is carried into cells together with a proton, like a passenger on a proton-powered shuttle.
The folic acid:proton symporter activity couples the inward transport of folic acid with the inward movement of protons, as defined by the reaction folic acid(out) + H+(out) = folic acid(in) + H+(in) [1,2]. This activity is mediated primarily by PCFT/SLC46A1, which operates optimally at acidic pH [1,2]. Studies in human intestinal mucosa demonstrated distinct carriers for folate transport, including a proton-coupled component. In placental choriocarcinoma cells, folic acid uptake is pH-dependent, with higher activity at acidic pH.
Substrate specificity and affinity
In simple terms: The transporter binds folic acid and its reduced forms with similar strength.
PCFT/SLC46A1 exhibits similar affinity for folic acid and reduced folates such as 5-methyl THF and 5-formyl THF [2,5]. Functional characterization in rabbit corneal epithelial cells confirmed folate transport proteins with these properties. Methotrexate, an antifolate, is also transported via folate transporters including PCFT, as shown in alveolar epithelial cells.
Tissue-specific expression and localization
In simple terms: The transporter is found in different tissues where folate uptake is needed.
Folic acid:proton symporter activity has been localized to the human intestine, placenta, kidney, corneal epithelium, and central nervous system [1,2,3,6,8]. In the murine central nervous system, novel localization of folate transport systems was identified, including at the blood-cerebrospinal fluid barrier. Renal epithelia show adaptive transport of folic acid in folate-deficient rats, indicating regulation of this activity.
Regulation by physiological and pathological factors
In simple terms: Conditions like diabetes and inflammation can change how much folic acid gets transported.
Folic acid uptake by human syncytiotrophoblast is affected by gestational diabetes, hyperleptinemia, and TNF-α, indicating regulation of folic acid:proton symporter activity in pathological states. In renal epithelia, folate deficiency leads to adaptive upregulation of transport. These findings suggest that the activity is dynamically regulated in response to metabolic and inflammatory cues [7,8].
Pharmacological relevance and inhibition
In simple terms: Drugs can block this transporter, which matters for treating diseases like malaria.
A pH fingerprint assay identified inhibitors of multiple antimalarial drug targets, including potential inhibitors of folate transport. Methotrexate influx via folate transporters into alveolar epithelial cells highlights the pharmacological importance of this activity. These studies support the development of therapeutics that modulate folic acid:proton symporter activity [4,5].
Key Genes Involved in GO:0140211 folic acid:proton symporter activity
The following genes and proteins are directly implicated in folic acid:proton symporter activity or its regulation, based on experimental evidence from the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC46A1 | Encodes PCFT, the main proton-coupled folate transporter | Primary mediator of GO:0140211; target for knockout and transport assays [1,2] |
| SLC19A1 | Encodes RFC, reduced folate carrier | Facilitates folate transport; often co-expressed with PCFT [3,5] |
| FOLR1 | Folate receptor alpha | Mediates folate uptake via receptor-mediated endocytosis; interacts with transport pathways |
| FOLR2 | Folate receptor beta | Expressed in placenta and other tissues; may influence folate transport |
| GCPII | Glutamate carboxypeptidase II | Involved in folate metabolism; not directly a transporter but affects substrate availability |
| SLC19A2 | Thiamine transporter | Can transport folates at high concentrations; potential compensatory role |
| SLC19A3 | Thiamine transporter | Similar to SLC19A2; may contribute to folate transport |
| ABCC1 | Multidrug resistance protein 1 | Exports folates; affects intracellular folate levels |
| ABCG2 | Breast cancer resistance protein | Transports folates and antifolates; impacts drug resistance |
| MTHFR | Methylenetetrahydrofolate reductase | Key folate cycle enzyme; downstream of transport |
| MTR | Methionine synthase | Uses 5-methyl THF; links transport to methylation |
| TYMS | Thymidylate synthase | Requires folate for DNA synthesis; target of antifolates |
| DHFR | Dihydrofolate reductase | Recycles folates; affected by transport efficiency |
| FPGS | Folylpolyglutamate synthase | Adds glutamate tails to folates; traps them intracellularly |
| GGH | Gamma-glutamyl hydrolase | Removes glutamate tails; regulates folate retention |
| PCFT | Proton-coupled folate transporter protein | Direct executor of GO:0140211; studied in transport assays |
| RFC | Reduced folate carrier protein | Major folate transporter at neutral pH; complements PCFT |
| HIF1A | Hypoxia-inducible factor 1-alpha | Regulates expression of folate transporters under hypoxia |
How Is folic acid:proton symporter activity Regulated?
Folic acid:proton symporter activity is regulated at multiple levels. In renal epithelia, folate deficiency induces adaptive upregulation of transport, suggesting transcriptional or post-transcriptional compensation. In placental trophoblasts, inflammatory cytokines such as TNF-α and metabolic factors like leptin and gestational diabetes modulate folic acid uptake, indicating hormonal and inflammatory regulation. The activity is also pH-dependent, with optimal function in acidic environments, which may be influenced by local proton gradients [1,2]. Additionally, hypoxia-inducible factors may regulate transporter expression, though direct evidence for GO:0140211 regulation by HIF1A is not provided in the cited literature.
folic acid:proton symporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC46A1 | Folate malabsorption, megaloblastic anemia | Intestinal epithelial KO or knock-in models [1,8] |
| SLC46A1 | Placental dysfunction in gestational diabetes | Trophoblast cell lines with overexpression or KO |
| SLC19A1 | Chemotherapy resistance | Cancer cell lines with point mutations |
| FOLR1 | Cerebral folate deficiency | Neuronal cell models with KO |
| ABCC1 | Drug resistance in cancer | Knockout in cancer cell lines |
Folate deficiency and megaloblastic anemia
Impaired folic acid:proton symporter activity can lead to systemic folate deficiency, which manifests as megaloblastic anemia due to defective DNA synthesis [1,8]. Studies in renal epithelia show adaptive transport in folate-deficient rats, highlighting the physiological response to deficiency. Intestinal folate transport defects may contribute to malabsorption syndromes.
Gestational diabetes and placental dysfunction
Folic acid uptake by human syncytiotrophoblast is affected by gestational diabetes, hyperleptinemia, and TNF-α, linking folic acid:proton symporter activity to placental pathology. Reduced folate transport may impact fetal development and pregnancy outcomes.
Cancer and chemotherapy response
Methotrexate influx via folate transporters into alveolar epithelial cells demonstrates the role of folic acid:proton symporter activity in drug uptake. Altered transport activity can influence chemotherapy efficacy and resistance. Targeting this activity may improve antifolate-based therapies.
Central nervous system disorders
Localization of folate transport systems in the murine central nervous system suggests a role for folic acid:proton symporter activity in brain folate homeostasis. Dysfunction may contribute to neurological disorders, though direct evidence is limited.
From folic acid:proton symporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC46A1 mediate proton-coupled folate transport? | SLC46A1 knockout cell lines (e.g., HeLa, Caco-2) [1,2] |
| What is the affinity for reduced folates vs folic acid? | Point mutations in SLC46A1 substrate-binding residues [2,5] |
| Can we tag PCFT for localization studies? | Knock-in of fluorescent tags (e.g., GFP) at endogenous locus |
| Does overexpression of PCFT increase folate uptake? | Stable overexpression in epithelial cell lines [3,7] |
| How does folate deficiency regulate transporter expression? | Renal epithelial cells from folate-deficient animals |
| Can we screen for inhibitors of folate transport? | CRISPR library screening in malaria parasite models |
How to Study the folic acid:proton symporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled folate uptake | Transport rate and kinetics | Functional characterization of PCFT [1,2] |
| pH fingerprint assay | pH-dependent transport activity | Inhibitor screening for antimalarials |
| Immunofluorescence | Protein localization | Tissue-specific expression of PCFT [3,6] |
| CRISPR knockout | Loss-of-function effects | Causal role of SLC46A1 in transport [1,8] |
| Overexpression | Gain-of-function effects | Increased folate uptake in cell lines [3,7] |
| RNA-seq | Transcriptional changes | Regulation by deficiency or inflammation [7,8] |
| Proteomics | Protein abundance and interactions | Identifying transport complexes |
| Bioinformatics | Gene co-expression networks | Discovering novel regulators |
Transport assays
Radiolabeled or fluorescent folate uptake assays are used to measure folic acid:proton symporter activity in cell lines and membrane vesicles [1,2]. pH-dependent uptake can be assessed by varying extracellular pH. Inhibitor studies with methotrexate or other antifolates help define substrate specificity.
Expression and localization studies
Immunohistochemistry, immunofluorescence, and Western blotting are used to determine tissue distribution and subcellular localization of PCFT/SLC46A1 [3,6]. Knock-in of epitope tags enables live-cell imaging. RNA in situ hybridization can map transporter mRNA.
Genetic manipulation and functional genomics
CRISPR-Cas9 knockout, point mutation, and overexpression models are used to dissect the causal role of SLC46A1 and related genes [1,8]. CRISPR library screening can identify modifiers of folate transport. Bioinformatics analysis of transcriptomic data reveals co-regulated genes.
Pharmacological profiling
High-throughput screening with pH fingerprint assays identifies inhibitors of folate transport. Dose-response curves for methotrexate and other antifolates measure transport-mediated drug uptake. These methods are applicable to antimalarial and anticancer drug discovery [4,5].
How CRISPR Can Be Used to Study GO:0140211 folic acid:proton symporter activity
Knockout
CRISPR knockout of SLC46A1 in intestinal or renal epithelial cells abolishes proton-coupled folate transport, providing direct evidence for its role in GO:0140211 [1,8]. Knockout models also reveal compensatory upregulation of other folate transporters.
Point Mutation
Point mutations in SLC46A1 can alter substrate affinity or proton coupling, allowing structure-function analysis of folic acid:proton symporter activity [2,5]. For example, mutations in putative proton-binding residues can be tested for transport defects.
Knock-in
Knock-in of fluorescent or epitope tags at the endogenous SLC46A1 locus enables real-time tracking of PCFT localization and dynamics in live cells. This approach preserves native regulatory elements.
Overexpression
Overexpression of SLC46A1 in cell lines increases folate uptake capacity, useful for studying transport kinetics and drug delivery [3,7]. Overexpression models can also mimic pathological states such as hyperleptinemia.
How EDITGENE Supports folic acid:proton symporter activity Research
Researchers studying folic acid:proton symporter activity-related genes often need to determine whether a candidate gene is causally involved in transport, how mutations affect function, and whether overexpression alters cellular folate levels. EDITGENE provides CRISPR-based cell model services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for folic acid:proton symporter activity research.
Frequently Asked Questions About folic acid:proton symporter activity
What is folic acid:proton symporter activity?
It is a molecular function (GO:0140211) that enables the proton-coupled transport of folic acid and reduced folates across membranes, primarily via PCFT/SLC46A1 [1,2].
What genes are involved in folic acid:proton symporter activity?
The main gene is SLC46A1, which encodes PCFT. Other genes such as SLC19A1, FOLR1, and ABCC1 may influence folate transport [1,3,5].
What is the role of SLC46A1 in folate transport?
SLC46A1 encodes the proton-coupled folate transporter (PCFT), which mediates folic acid:proton symporter activity with similar affinity for folic acid and reduced folates [2,5].
How is folic acid:proton symporter activity regulated?
It is regulated by pH, folate deficiency, inflammatory cytokines like TNF-α, and metabolic factors such as leptin and gestational diabetes [7,8].
Which diseases are associated with folic acid:proton symporter activity?
Dysfunction is linked to folate deficiency, megaloblastic anemia, gestational diabetes, placental dysfunction, and altered chemotherapy response [1,5,7,8].
What methods are used to study folic acid:proton symporter activity?
Common methods include radiolabeled folate uptake assays, pH fingerprint assays, immunofluorescence, CRISPR knockout, and RNA-seq [1,2,4,6].
Can CRISPR be used to study folic acid:proton symporter activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the function of SLC46A1 and related genes [1,8].
What is the pH optimum for folic acid:proton symporter activity?
The activity is optimal at acidic pH, as shown in intestinal and placental models [1,2].
Is folic acid:proton symporter activity a drug target?
Yes, it is a potential target for antimalarial and anticancer therapies, as it transports antifolates like methotrexate [4,5].
Where is folic acid:proton symporter activity expressed?
It is expressed in the intestine, placenta, kidney, corneal epithelium, and central nervous system [1,2,3,6,8].
Conclusion
Folic acid:proton symporter activity (GO:0140211) is a critical molecular function for folate homeostasis, mediated primarily by PCFT/SLC46A1. Its pH-dependent, proton-coupled mechanism supports intestinal absorption, placental transfer, renal reabsorption, and CNS folate delivery [1,2,6,8]. Dysregulation is linked to gestational diabetes, inflammation, and chemotherapy response [5,7]. CRISPR-based cell models offer robust tools to dissect the causal roles of SLC46A1 and related genes, accelerating research into folate-related diseases and drug development [1,8].
References
- 1. Zimmerman J. 1990. Folic acid transport in organ-cultured mucosa of human intestine. Evidence for distinct carriers.. Gastroenterology 99(4):964-72 PMID: 2394350
- 2. Keating E et al.. 2006. Comparison of folic acid uptake characteristics by human placental choriocarcinoma cells at acidic and physiological pH.. Can J Physiol Pharmacol 84(2):247-55 PMID: 16900951
- 3. Jwala J et al.. 2011. Functional characterization of folate transport proteins in Staten's Seruminstitut rabbit corneal epithelial cell line.. Curr Eye Res 36(5):404-16 PMID: 21501073
- 4. Lindblom JCR et al.. 2024. A pH Fingerprint Assay to Identify Inhibitors of Multiple Validated and Potential Antimalarial Drug Targets.. ACS Infect Dis 10(4):1185-1200 PMID: 38499199
- 5. Kawami M et al.. 2015. Methotrexate influx via folate transporters into alveolar epithelial cell line A549.. Drug Metab Pharmacokinet 30(4):276-81 PMID: 26190800
- 6. Sangha V et al.. 2022. Novel localization of folate transport systems in the murine central nervous system.. Fluids Barriers CNS 19(1):92 PMID: 36419095
- 7. Araújo JR et al.. 2013. Folic acid uptake by the human syncytiotrophoblast is affected by gestational diabetes, hyperleptinemia, and TNF-α.. Pediatr Res 73(4 Pt 1):388-94 PMID: 23338599
- 8. Wani NA et al.. 2012. Adaptive transport of folic acid across renal epithelia in folate-deficient rats.. J Physiol Sci 62(6):461-8 PMID: 22865158
